Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression

JTO Clinical and Research Reports(2022)10.1016/j.jtocrr.2022.100369Source: DataRank Database

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression is a research paper published in JTO Clinical and Research Reports (2022). On theSindex it has a DataRank of 0.312. It has been cited 7 times.

N/A

0.312DataRank · unranked

Scored on demand from live citation data

7 citations

Download PDF

Cite:

Linked data & code

bioproject doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 0.56)OA: goldTopics (18)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (14)

Rastislav Horos ORCID,Paul Kittner,Mustafa Kahraman ORCID,Tobias Sikosek ORCID,Franziska Hinkfoth

Live enrichment

PubMed:35880086 PMC:PMC9307680 OpenAlex:https://openalex.org/W4283162095

Merck KGaA

AstraZeneca

Incyte

Novartis

Roche

Takeda Pharmaceutical Company

Pfizer

Boehringer Ingelheim

Chiesi Farmaceutici

Eli Lilly and Company

GlaxoSmithKline

Merck Sharp and Dohme

Sanofi-Aventis Deutschland

Amgen

Bayer

Bristol-Myers Squibb

FWCI

0.56

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtocrr.2022.100369

publisherhttps://doi.org/10.1016/j.jtocrr.2022.100369

publisherhttps://api.elsevier.com/content/article/PII:S2666364322000935?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364322000935?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35880086

Fields of Study

Cancer Immunotherapy and BiomarkersMicroRNA in disease regulationFerroptosis and cancer prognosis

Keywords

Hazard ratioImmunotherapyMedicineOncologyInternal medicineConfidence intervalStage (stratigraphy)CohortBiomarkerProportional hazards modelCancerBiologyNSCLCPD-L1miRNAs

Sustainable Development Goals

SDG 0: Good health and well-being